Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Accured Expenses (2017 - 2025)

Protagonist Therapeutics' Change in Accured Expenses history spans 9 years, with the latest figure at $5.4 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 67.57% year-over-year to $5.4 million; the TTM value through Dec 2025 reached $4.6 million, up 6.69%, while the annual FY2025 figure was $4.6 million, 6.69% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $5.4 million at Protagonist Therapeutics, down from $7.5 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $13.0 million in Q3 2021 and bottomed at -$14.5 million in Q4 2021.
  • The 5-year median for Change in Accured Expenses is $693000.0 (2021), against an average of -$478400.0.
  • The largest annual shift saw Change in Accured Expenses tumbled 659.29% in 2022 before it skyrocketed 353.05% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at -$14.5 million in 2021, then surged by 68.39% to -$4.6 million in 2022, then fell by 16.35% to -$5.3 million in 2023, then surged by 160.47% to $3.2 million in 2024, then skyrocketed by 67.57% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Change in Accured Expenses are $5.4 million (Q4 2025), $7.5 million (Q3 2025), and $3.4 million (Q2 2025).